Skip to main content

Advertisement

SpringerLink
Log in

Anticancer effects of imatinib via immunostimulation

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Imatinib represents the quintessential example of a targeted anticancer agent that directly suppresses the activation of oncogenic tyrosine kinases. Surprisingly, in the context of gastrointestinal stromal tumors (GISTs), the therapeutic effect of imatinib crucially depends on the reactivation of an anticancer immune response (pages 1094–1100).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Putative scenarios in imatinib-treated GIST.

Katie Vicari

References

  1. Hanahan, D. & Weinberg, R.A. Cell 144, 646–674 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Pierotti, M.A., Tamborini, E., Negri, T., Pricl, S. & Pilotti, S. Nat. Rev. Clin. Oncol. 8, 161–170 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Balachandran, V.P. et al. Nat. Med. 17, 1094–1100 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Taieb, J. et al. Nat. Med. 12, 214–219 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. Borg, C. et al. J. Clin. Invest. 114, 379–388 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Delahaye, N.F. et al. Nat. Med. 17, 700–707 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Ghiringhelli, F. et al. J. Exp. Med. 202, 1075–1085 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Okada, M. et al. Blood 103, 2299–2307 (2004).

    Article  CAS  PubMed  Google Scholar 

  9. Zitvogel, L., Kepp, O. & Kroemer, G. Cell 140, 798–804 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Mohty, M. et al. Blood 103, 4666–4668 (2004).

    Article  CAS  PubMed  Google Scholar 

  11. Catellani, S., Pierri, I., Gobbi, M., Poggi, A. & Zocchi, M.R. PLoS ONE 6, e18925 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Preudhomme, C. et al. N. Engl. J. Med. 363, 2511–2521 (2010).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laurence Zitvogel is at the Institut Gustave Roussy (IGR), Villejuif, France; the Center of Clinical Investigations, IGR, Villejuif, France; and the University of Paris Sud, Villejuif, France.,

    Laurence Zitvogel

  2. the Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, IGR, Villejuif, France,

    Laurence Zitvogel

  3. Guido Kroemer is at INSERM U848, Villejuif, France; the Centre de Recherche des Cordeliers, Paris, France; the Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France; and the Université Paris Descartes, Sorbonne Paris Cité Faculté de Médecine, Paris, France.,

    Guido Kroemer

  4. the Metabolomics Platform, IGR, Villejuif, France,

    Guido Kroemer

Authors
  1. Laurence Zitvogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Kroemer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Laurence Zitvogel or Guido Kroemer.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zitvogel, L., Kroemer, G. Anticancer effects of imatinib via immunostimulation. Nat Med 17, 1050–1051 (2011). https://doi.org/10.1038/nm.2429

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2429

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation